Such ups and downs will likely be the pattern for Rigetti stock until the quantum computing industry matures. Wall Street analysts have a median 12-month price target of $30.50 per share on the stock, ...

Yet one of the easiest traps to fall into is offering advice too soon. "We'll often jump into, 'How can I fix this? How can I ...

With states still brawling over how to share dwindling flows, the Trump administration is about to take control.

In Rough Edges, Mike Rothschild writes about fringe groups, conspiracy theories and how the Internet broke our brains. This column is part of TPM Cafe, TPM’s home for opinion and news analysis. The ...

Largely due to overpayments, Massachusetts registered a 12.5% error rate for SNAP benefits in fiscal year 2025, which could put the state on the hook to cover more of ...

Dear Annie: I am a 31-year-old woman, and I’ve been with my boyfriend for five years. We’ve been talking about marriage for the past two — talking about it and talking about it. Every time it comes up ...

Dear Tired of Waiting: Five years in, two years of “soon” — at some point, that word stops meaning anything. You’ve already asked directly, so skip the hints and have a plain conversation: You want to ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Originally published on goodrx.com, part of the BLOX ...

GREENSBORO, N.C. — Medicare coverage includes doctor visits, hospital stays, and medicines. As of July 1, 2026, Medicare now covers GLP-1's for just $50 a month. "You've got to be a Medicare Part D ...

Medicare began covering certain GLP-1 weight loss drugs on July 1, 2026, giving millions of eligible beneficiaries access to medications that can help manage weight and improve overall health — all ...

Shield is the first and only FDA-approved blood test for primary colorectal cancer screening in average-risk adults age 45 and older and can be completed with just a blood draw during a routine doctor ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now ...